Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.60 |
| ▸ | CCKBR | P32239 | 3/20 | 0.40 |
| ▸ | FPR2 | P25090 | 5/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631603 | 1.00 | F10 (0.60) | F10CCKBRFPR2USP30MAPT | |
| SCHEMBL5633540 | 0.89 | F10 (0.49) | F10FPR2SMN1; SMN2 | |
| SCHEMBL5633543 | 0.89 | F10 (0.49) | F10FPR2SMN1; SMN2 | |
| SCHEMBL5633494 | 0.86 | F10 (0.57) | F10FPR2USP30MAPTSMN1; SMN2 | |
| SCHEMBL5633501 | 0.86 | F10 (0.57) | F10FPR2USP30MAPTSMN1; SMN2 | |
| SCHEMBL5633316 | 0.84 | F10 (0.46) | F10FPR2MAPTSMN1; SMN2CNR1 | |
| SCHEMBL5633314 | 0.84 | F10 (0.46) | F10FPR2MAPTSMN1; SMN2CNR1 | |
| SCHEMBL5633625 | 0.84 | F10 (0.59) | F10CCKBRFPR2USP30MAPT | |
| SCHEMBL5633623 | 0.84 | F10 (0.59) | F10CCKBRFPR2USP30MAPT | |
| SCHEMBL5630439 | 0.82 | EP300 (0.46) | F10FPR2MAPTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183277-B2 | Alpha-((aryl or heteroaryl)ureido or carbamoyloxy)-N-heteroaryl amides; blood-coagulation factor Xa and VIIa inhibitors; synergistic mixtures with other antitumor agents or anticoagulants | MERCK PATENT GMBH (DE) | 2007-02-27 | — | — | US | claimed |
| US-20050171154-A1 | Carboxylic acid amides | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| US-7183277-B2 | Alpha-((aryl or heteroaryl)ureido or carbamoyloxy)-N-heteroaryl amides; blood-coagulation factor Xa and VIIa inhibitors; synergistic mixtures with other antitumor agents or anticoagulants | MERCK PATENT GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20050171154-A1 | Carboxylic acid amides | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171154-A1 | Carboxylic acid amides | F11, F12, F2 | F10 4/4885CCKBR 544/4885FPR2 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.